One of the few key areas on which Donald Trump broke with Republican Party orthodoxy was lowering prices on prescription drugs. In fact, shortly before taking office, he complained bitterly about the pharmaceutical industry’s powerful lobbyists, and said drug companies are “getting away with murder.”
For some on the left, this offered at least some hope that the Trump administration would be progressive on the issue, though those hopes faded soon after the president took office. In late January, Trump reversed course, saying he no longer wanted to use the government’s buying power to lower costs, denouncing such a policy as “price fixing.”
Vox explained at the time that the White House’s approach appeared to amount to little more than “lowering taxes” and “getting rid of regulations.”
That turned out to be exactly right. Five months later, the New York Times reports on a draft of an executive order the president intends to sign on drug prices that “appears to give the pharmaceutical industry much of what it has asked for.”
The draft, which The New York Times obtained on Tuesday, is light on specifics but clear on philosophy: Easing regulatory hurdles for the drug industry is the best way to get prices down.









